KDIGO Diagnostic tests and therapeutic targets for anemia of CKD - - PowerPoint PPT Presentation

▶
kdigo
SMART_READER_LITE
LIVE PREVIEW

KDIGO Diagnostic tests and therapeutic targets for anemia of CKD - - PowerPoint PPT Presentation

Mar 26, 2024 226 likes •429 views

KDIGO Diagnostic tests and therapeutic targets for anemia of CKD Dorine W. Swinkels, Laboratory Physician Radboudumc expertise center for iron disorders, Nijmegen, the Netherlands D ISCLOSURES I am an employee of the Radboud University Medical

slide-1
SLIDE 1

Diagnostic tests and therapeutic targets for anemia of CKD

Dorine W. Swinkels, Laboratory Physician

Radboudumc expertise center for iron disorders, Nijmegen, the Netherlands

KDIGO

slide-2
SLIDE 2

DISCLOSURES

I am an employee of the Radboud University Medical Center that serves the medical, scientific and commercial community with hepcidin reference material and hepcidin and toxic iron measurements at a fee-for service basis (www.hepcidinanalysis.com) I participate in the clinical and scientific advisory board of Silence therapeutics, that develops hepcidin targeting compounds

KDIGO

slide-3
SLIDE 3

Biomarkers of iron metabolism

ferritin sTfR hepcidin retis, erys Store circulation Red cell (precursor)

KDIGO

slide-4
SLIDE 4

Absolute iron deficiency

Iron store Circulation Bone marrow erythropoiesis Iron stores ferritin sTfR transferrin ferri- transferrin hepcidin iron reti’s or ery’s liver spleen

KDIGO

slide-5
SLIDE 5

Primary overload syndromes, hereditary hemochromatosis

Iron stores

ferritin sTfR transferrin ferri- transferrin hepcidin iron/NTBI retis or erys Bone marrow erythropoiesis Circulation

KDIGO

slide-6
SLIDE 6

Functional iron deficiency (= iron distribution disorder)

ferritin sTfR transferrin ferri- transferrin hepcidin iron reti’s or ery’s Iron stores Bone marrow erythropoiesis Circulation

Iron-restricted erythropoiesis: insufficient iron mobilization from the (otherwise adequate) body iron stores to meet iron demands of erythroid precursors

KDIGO

slide-7
SLIDE 7

Elevated hepcidin→ iron distribution/mobilisation disorder Treatment with ESA → high iron demand

  • Fe

++

Functional iron deficiency

Functional iron deficiency

KDIGO

slide-8
SLIDE 8

FERRITIN

  • Reflects overall storage iron (but is chiefly derived from macrophages)
  • Reference values vary and depend on age, gender (and race), and are not always useful as cut-off
  • Robust data on clinical decision limits/diagnostic accuracy/thresholds are lacking
  • Levels are increased in patients with liver diseases, metabolic syndrome, inflammation, infection
  • Levels are decreased in absolute ID;
  • Overall, iron deficiency< 12-30 (specific); iron replete > 100; iron overload > 200-300 µg/l
  • In CKD, proposed levels:
  • absolute ID in non-HD < 100 µg/l and HD < 200 µg/l
  • functional ID vary between 100-1200 µg/l
  • In CKD: inflammation and elevated hepcidin levels → iron distribution to RES
  • (low TSAT and) relatively high ferritin for body iron levels
  • long term safety of RES iron loading in CKD is unclear
  • MRI liver cannot distinguish between parenchymal and RES iron overload.
  • Algorithmes to correct ferritin for inflammatory markers are not universally applicable (vary with type
  • f inflammation, stage of disease)

Blackmore, 2008; Ferraro, 2018; Harris, 2007; KDIGO, 2012; Thomas, 2013; Thurnham, 2010; Suchdev, 2017; Daru, 2017

KDIGO

slide-9
SLIDE 9

TRANSFERRIN SATURATION (TSAT %)

  • Reflects circulating iron levels
  • Comprises 2 measurements: 1. iron and 2. TIBC (=UIBC+ Iron) or transferrin
  • Calculation: TSAT (%) = iron/ TIBC x 100 %; TIBC (µmol/L)= transferrin (g/L) x

25.2

  • In patients with inflammation/CKD, iron is more decreased than transferrin →

decrease in TSAT→ less iron available for erythropoiesis

  • TSAT < 20%: absolute or functional iron deficiency; some guidelines for CKD <

25-30%

  • TSAT> ≈80%, formation of toxic iron forms (non transferrin bound iron, NTBI)
  • In patients with hyperferritinemia,
  • high TSAT is associated with primarily parenchymal iron overload
  • low TSAT is associated with primarily RES iron overload
  • In patients with non-HD CKD, low TSAT is associated with higher mortality

Thomas DW, BJH 2013; KDIGO, 2012l Kovesdy CP, CJASN 2009; Eisinga M, BMC Nephrology 2018

KDIGO

slide-10
SLIDE 10

HEPCIDIN in CKD results from the relative strengths of opposing stimuli

Swinkels & Wetzels, NDT 2008; Yamada, Kidney Int 2009

Chronic Kidney Disease EPO  inflammation  hepcidin gene red cell survival  blood loss erythropoiesis  anemia / hypoxia hepcidin  Exogenous EPO erythropoiesis  GFR  iron stores IV iron

KDIGO

slide-11
SLIDE 11

Hepcidin is increased in most patients with CKD

→ In majority of studies controls and patients are not matched for age, gender and iron

supplementation (ferritin)

Tomosugi, 2006; Ashby, 2009; Zaritsky, 2009; Peters, 2010, Camprostini, 2010; Kurugano, 2010; Troutt, 2013; Valenti, 2013

Peters, 2010

KDIGO

slide-12
SLIDE 12

Parameter/outcome study population association with hepc. remarks elevated ferritin HD/non-HD +++ major determinant low GFR non-HD + inconsistent CRP and Il-6 HD/non-HD ++ in most studies ESA resistance or response HD +/- inconsistent effect of iron supplementation on Hb HD

  • small study, no

control group type of dialyzer HD +/- inconsistent renal anemia non-HD + prediction atherosclerosis HD + CV events/arterial stifness

Tomosugi 2006; Kato 2008; Ashby 2009; Weiss 2009; Costa 2009, Valenti 2009; Zaritsky 2009; Peters 2010; van der Putten 2010; Weiss, 2009; Kuragano 2010; Camprostini , 2010; Tessitore 2010; Ford, 2010; Kroot, 2011; Nakanishi, 2011; Uehata 2012; van der Weerd 2012; Peters, 2012; Nihata, 2012; Pelusi, 2013; Troutt, 2013; Mercadel, 2014; Ulu, 2014; Valenti, 2014; van der Weerd, 2015

Hepcidin and CKD

Conclusion

Hepcidin alone is:

  • 1. not an anemia

management tool

  • 2. A biomarker for

cardiovascular disease? High within subject variation in hepcidin in time

KDIGO

slide-13
SLIDE 13

HEMOGLOBIN

  • Overall, the exact Hb threshold below which a health outcome is detrimental is

undefined

  • In CKD, Hb level at which ESA treatment should be initiated to increase quality
  • f life is unclear
  • In CKD, Hb target for ESA treatment is 10-12 g/L, based on optimal ratio benefit

(quality of life)/risk (stroke and thromboembolic events)

  • Whether Hb targets in CKD should depend on age, gender, ethnicity, genetic

factors, altitude, and hypoxia (smoking) is unclear

  • Hb not only reflects body iron status; in CKD also other factors contribute to

anemia: inflammation, reduced red blood cell survival and genetic factors

NOTE: also ID (without anemia) may cause symptoms

Garcia-Casal, 2019; Johansen, 2010; Parfrey, 2005, 2010; Canadian Erythropoietin Study Group:1990; Pfeffer, 2009; Benyamin, 2014; Pelusi, 2013; Pasricha, 2014; Pratt, 2018; Houston, 2018

KDIGO

slide-14
SLIDE 14

RED BLOOD CELL MARKERS

RetHb content

  • Reticulocyte Hb content is Hb content (MCH) of reticulocytes and available on various

automated hematology platforms

  • Early marker for iron restricted erythropoiesis due to absolute or functional iron deficiency (before

development of anemia)

  • Monitoring response to therapy:
  • a guidance for diagnosing functional ID and optimizing iron therapy in patients receiving

ESA for end stage renal failure

  • an early marker of erythropoietic response to iron supplementation
  • Absence of clinical decision limits

% hypochromic cells:

  • Time averaged marker of iron restricted erythropoiesis
  • Diagnosing functional ID in patients receiving ESA
  • Sensitive to pre-analytical bias (time to analysis)
  • Absence of clinical decision limits.

Piva, 2015; Brugnara, 2013; Ulrich 2005, Fishbane, 1997; 2001; Goodnough, 2010; Mittman, 1997; brugnara 1994; McDougall, BMJ 1992; Ratcliffe, AJKD 2016

KDIGO

slide-15
SLIDE 15

STFR

  • Increases when iron availability does not meet erythropoietic needs
  • Less suitable as a marker of functional ID in CKD since:
  • CKD patients often have erythroid hypoplasia (that masks ID-induced increases)
  • in CKD patients receiving ESA, sTfR reflects more erythroid response to ESA than to (functional) ID

Eschbach, 1992; Fernandez-rodriguez, 1999; Ahluwalia, 1997; Beguin 1993; Wish, 2006; Huebers, 1990; Spoto, 2019; Honda, 2016; Hanudel, 2018

ERYTHROFERRONE

  • Produced by erythroblast in response to EPO; inhibits hepcidin production
  • Elevated in HD-CKD with dose response to ESA treatment
  • No clear relation with hepcidin in CKD
  • Associated with mortality and CV events in non-HD and HD CKD patients,

mechanism needs elucidation

KDIGO

slide-16
SLIDE 16

Several iron and RBC biomarkers are not standardized

True value Equivalent results

Standardization

Standardized: automated Hb Moderately standardized: ferritin and transferrin/TIBC (Blackmore 2018) Non standardized: sTfR (Thorpe, 2010; Pfeiffer, 2017), erythroferrone, RetHb, % hypochromic cells, hepcidin*

Harmonization

*Hepcidin standards have recently been developed allowing standardisation (van der Vorm, 2016; Diepeveen, 2019)

KDIGO

slide-17
SLIDE 17

HEPCIDIN ANTAGONISTS

  • Multiple strategies that counter the effect of hepcidin in iron-restrictive

disorders (such as CKD) have been described

  • Phase 1 and 2 of some of these compounds have been completed.
  • Some programs have been stopped after phase 1/2
  • Overall, these compounds show increase in TSAT and decrease in hepcidin

levels in healthy volunteers, and patients with inflammatory diseases and CKD; clear effects on Hb, RetHb in CKD patients have yet to be shown.

  • Decrease hepcidin levels (EPO dependent and independent)
  • Increase in intestinal iron absorption
  • Increase use of iron via hepcidin dependent and independent mechanism

Schwoebel, 2013; Boyce, 2016; van Eijk 2014, Hohlbaum, 2018, Galli, 2018; Sheetz, 2019; Barrington, 2016 (abstract); Petzer, 2018 (review); Renders, 2019; Anderson 2013; Koury, 2015 (review)

HIF STABILIZERS

Compounds that interfere with iron metabolism in CKD and affect iron biomarkers

KDIGO

slide-18
SLIDE 18

Combined iron and RBC biomarkers provide insight in iron dyshomeostasis in CKD, and may contribute to treatment selection

Thanks to SR Pasrisha

Absolute Iron Deficiency (Anemia)

Low body iron stores Inadequate total iron available, Low ferritin Low transferrin saturation%, Low RetHb, High sTfR, Low hepcidin Iron supplementation

Functional Iron Deficiency

Normal body iron stores Inadequate mobilisation of iron Normal/elevated ferritin, Low transferrin saturation%, Low RetHb, Low- High sTfR, elevated hepcidin Elevated inflammatory markers ESA, anti-hepcidin, HIF-stabilizer (iron supplementation

Anemia of chronic disease

  • Erythroid suppression
  • Reduced red cell survival
  • Rel. EPO def.
  • Absolute ID and functional ID partly overlap
  • Absolute ID and anemia of chronic disease partly overlap
  • Functional Iron Deficiency and Anemia of Chronic Disease largely overlap

KDIGO

slide-19
SLIDE 19

TAKE HOME

➢Several conventional and innovative iron and RBC biomarkers

  • derived from stores, circulation and bone marrow

➢ Suitability biomarkers to define treatment strategies

  • individual biomarker: low
  • combination biomarkers (in clinical context): relatively high

➢ High ferritin + elevated TSAT → primarily parenchymal loading= rel. toxic + normal/low TSAT→ primarily RES loading=rel. safe (long term effects unknown) ➢ Clinical interpretation of biomarker results

  • often method dependent since assays are not standardized
  • low evidence for clinical decision limits: largely expert opinion base

KDIGO

slide-20
SLIDE 20

FUTURE DIRECTIONS AND RESEARCH NEEDS

  • Standardization of iron and RBC biomarkers
  • Elucidating clinical decision limits relevant for iron adequacy in CKD
  • Need for functional markers of iron deficiency beyond Hb
  • Identification of genetic loci that are associated with iron metabolism in CKD and

treatment outcomes → personalized treatment strategies

KDIGO